# Forensic Dossier: Study Forensics: Rapamycin for human longevity — promise vs proof

**Run ID:** `mech_study-forensics-031_claude_haiku_e9b6d5`  
**Task:** study-forensics-031 | study_forensics | hard | study_forensics  
**Timestamp:** 2026-04-06T15:45:30.100854+00:00  
**Task Family:** mechanism_vs_evidence  
**Trap Type:** strong_preclinical_weak_human  
**Ambiguity:** medium  

## Executive Summary

**Agents tested:** Claude Haiku
**Winner:** Claude Haiku — **40.0/100** (margin: 0.0)
**Failure modes:** unsupported_conclusion, wrong_answer
**Forensic flags:** 3
**Consistency findings:** 7
**Answer convergence:** all agents agree

## Score Matrix

| Agent | Correctness | Support Strength | Structural Reaso | Assumption Disci | Uncertainty Hand | Alternative Hypo | Self Monitoring  | Insight Depth | Mechanism Qualit | Communication Ef | **Total** |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Claude Haiku | 0.0/30 | 0.0/8 | 4.8/8 | 4.8/6 | 3.9/6 | 6.0/6 | 5.2/8 | 8.0/8 | 4.0/10 | 8.5/10 | **40.0/100** |

## Study Forensics Audit

### Claude Haiku

**Classification:** `solid` [x] (gold: `mechanism_vs_evidence`)
**Finding Recall:** 100%
**Matched Findings:** mechanism_not_demonstrated, decorative_uncertainty
**Extra Findings:** evidence_matches_claim, cautious_scope_control, none_or_minor, conclusion_exceeds_results, correlation_as_causation

## Reasoning Integrity Audit

### Claude Haiku
**Classification:** Correct and well-supported
**Load-bearing steps:** 0 / 7

## Mechanism Analysis

### Claude Haiku
| Aspect | Status |
|--------|--------|
| Concept named | :white_check_mark: effect |
| Mechanism described | :white_check_mark: (1 sentence(s)) |
| Grounded to case | :x: (0 sentence(s)) |

**Missing:** mechanism not grounded to case data

## Grounding Audit

### Claude Haiku
Conclusion claims: 1
- Direct support: 0
- Indirect support: 0
- Unsupported: 1
- Contradicted: 0

**Unsupported claims:**
- "solid"


## Forensic Flags

### Claude Haiku

- **[MAJOR]** `well_reasoned_wrong`: Wrong answer but structured reasoning — may have a subtle logic error
  - `final_answer`: "solid"
- **[MODERATE]** `unsupported_conclusion_claims`: 1/1 conclusion claims lack step support
  - `final_answer`: "solid"
- **[MODERATE]** `ungrounded_mechanism`: Mechanism named/described but not connected to case-specific data
  - `(mechanism analysis)`: "effect"


## Evidence Map

### Claude Haiku

**Correctness:** 0.0/30
  - (+) `final_answer`: "solid"
    _Agent's answer for correctness check_
  - Note: No match (got: solid)

**Support Strength:** 0.0/8
  - (-) `final_answer`: "solid"
    _Conclusion not supported by steps_
  - Note: Support classification: 0 load-bearing, 0 supporting, 0 mentioned / 7
  - Note: Reasoning graph: conclusion not well grounded

**Structural Reasoning:** 4.8/8
  - (+) `steps[2]`: "Checked for correlation vs. causation: The text does not claim rapamycin causes aging slowdown in humans. It reports wha"
    _Most informative reasoning step_
  - Note: 7 reasoning steps
  - Note: Low step utility: 0/7 steps contribute

**Assumption Discipline:** 4.8/6
  - (+) `assumptions[2]`: "The trial's primary endpoint (abdominal fat reduction) and secondary endpoint (lean muscle) are appropriate proxies for "
    _Most substantive assumption_
  - Note: 5/5 substantive assumptions

**Uncertainty Handling:** 3.9/6
  - (+) `uncertainties[0]`: "Whether the human trial's endpoints (abdominal fat, lean muscle) are truly appropriate proxies for aging effects—the tex"
    _Most substantive uncertainty_
  - (+) `confidence`: "confidence: 0.92"
    _Stated confidence level_
  - Note: 3 uncertainties (3 substantive)
  - Note: Confidence 0.92

**Alternative Hypothesis Quality:** 6.0/6
  - (+) `alternative_hypotheses[1]`: "Mechanism vs. evidence: Could argue the mTOR pathway description implies a mechanism in humans, but the text does not cl"
    _Most substantive alternative hypothesis_
  - Note: 2 alternative hypotheses considered
  - Note: 2/2 include rejection reasoning

**Self Monitoring Quality:** 5.2/8
  - (+) `self_check[5]`: "Could this text be improved? Yes—it could specify what 'modest' muscle gain means quantitatively, and could elaborate on"
    _Most substantive self-verification step_
  - (-) `self_check[4]`: "Is the expert caution justified? Yes, given the evidence gap and known risks."
    _Fluff self-check_
  - Note: 6 self-check items
  - Note: Self-check quality: 0 deep, 5 arithmetic, 1 fluff

**Mechanism Quality:** 4.0/10
  - (+) `(mechanism analysis)`: "Checked for correlation vs. causation: The text does not claim rapamycin causes aging slowdown in humans. It reports wha"
    _Mechanism description without case grounding_
  - Note: Names concept + describes mechanism (not grounded to case)

**Communication Efficiency:** 8.5/10
  - Note: Signal density: 0.72, 572 words

**Insight Depth:** 8.0/8
  - Note: Key insights: 2 full / 2


## Failure Analysis

### Claude Haiku

**CRITICAL:**
- **Wrong Answer** `[HIGH CONFIDENCE]`: Answer does not match expected 'mechanism_vs_evidence'
  - `final_answer`: "solid"
  - _Impacts: correctness_

**MAJOR:**
- **Wrong Answer** `[HIGH CONFIDENCE]`: Study classification incorrect: expected 'mechanism_vs_evidence', detected 'solid'
  - `final_answer`: "solid"
  - _Impacts: correctness_

**MODERATE:**
- **Unsupported Conclusion** `[MEDIUM CONFIDENCE]`: Final answer lacks load-bearing or supporting step grounding
  - `final_answer`: "solid"
  - _Impacts: support_strength_


## Consistency & Grounding Audit

### Claude Haiku

- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 1 has low overlap with final answer (0/10 content words)
  - `key_claims[0]`: "Mouse lifespan extension (10-25%) is well-replicated but does not translate to proven human aging ef"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 2 has low overlap with final answer (0/12 content words)
  - `key_claims[1]`: "The human trial was well-designed and tested relevant endpoints, but did not achieve its primary goa"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 3 has low overlap with final answer (0/10 content words)
  - `key_claims[2]`: "Expert consensus explicitly states no clinical evidence supports rapamycin for aging in humans"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 4 has low overlap with final answer (0/7 content words)
  - `key_claims[3]`: "Off-label use carries documented risks, especially for vulnerable populations"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 5 has low overlap with final answer (0/11 content words)
  - `key_claims[4]`: "The text maintains a clear epistemic boundary between animal data, human enthusiasm, and human evide"
- **[WARN]** `[HEURISTIC]` `claim_step_alignment`: Key claim 4 not well supported in reasoning steps (1/7 content words found)
  - `key_claims[3]`: "Off-label use carries documented risks, especially for vulnerable populations"
- **[NOTE]** `[MEDIUM CONFIDENCE]` `mechanism_gap`: Causal mechanism described but underlying concept not named
  - `final_answer`: "solid"


## Agent Profiles

### Claude Haiku (claude-haiku-4-5-20251001)
**Parse OK:** True | **Latency:** 10455ms

**Final Answer:** solid

**Confidence:** 0.92

**Assumptions:**
- The mouse lifespan extension data (10-25%) is accurately reported and represents genuine replication across labs
- The human trial described is indeed 'well-designed' as stated
- The trial's primary endpoint (abdominal fat reduction) and secondary endpoint (lean muscle) are appropriate proxies for aging effects
- The text accurately represents expert consensus on current evidence
- Off-label use of rapamycin does carry the risks mentioned for the populations cited

**Reasoning Steps:**
1. Identified the core claim structure: mouse data → human enthusiasm → human trial results → expert caution
2. Checked for mechanism vs. evidence issues: The text does NOT claim the mouse mechanism (mTOR inhibition) directly translates to humans. It acknowledges the gap by noting the human trial 'did not test whether the drug slows biological aging'
3. Checked for correlation vs. causation: The text does not claim rapamycin causes aging slowdown in humans. It reports what the trial found (safety, modest muscle gains, no fat reduction) without causal overreach
4. Checked for overclaim: The text explicitly states 'no clinical evidence yet shows rapamycin slows aging in people'—this is a clear epistemic boundary
5. Checked for decorative uncertainty: The uncertainty language is substantive and functional. It's not used to soften an overclaim; rather, it accurately describes the evidence gap
6. Checked for confounders: The text does not make causal claims about the trial results that would require confounder discussion. It reports outcomes, not mechanisms
7. Assessed expert caution: The caution about off-label use and risks is appropriately grounded in the lack of human evidence and known safety concerns

**Key Claims:**
- Mouse lifespan extension (10-25%) is well-replicated but does not translate to proven human aging effects
- The human trial was well-designed and tested relevant endpoints, but did not achieve its primary goal and did not measure biological aging
- Expert consensus explicitly states no clinical evidence supports rapamycin for aging in humans
- Off-label use carries documented risks, especially for vulnerable populations
- The text maintains a clear epistemic boundary between animal data, human enthusiasm, and human evidence

**Alternative Hypotheses:**
- Overclaim: Could argue the text implies rapamycin *might* slow aging by juxtaposing mouse data with human use, but the text explicitly denies this claim and attributes enthusiasm to 'enthusiasts,' not evidence
- Mechanism vs. evidence: Could argue the mTOR pathway description implies a mechanism in humans, but the text does not claim this—it only describes the mechanism in mice and notes the human trial didn't test aging

**Uncertainties:**
- Whether the human trial's endpoints (abdominal fat, lean muscle) are truly appropriate proxies for aging effects—the text doesn't claim they are, but I'm assuming the trial design was sound as stated
- The specific risks of off-label rapamycin use beyond those mentioned; the text cites cancer as an example but may not be exhaustive
- Whether 'modest' muscle increase in women is clinically meaningful—this is a judgment call not fully specified in the text

**Self-Verification:**
- Did I overidentify problems? No. The text is carefully hedged and does not make unsupported causal claims about humans.
- Did I miss overclaiming? No. The text explicitly denies the claim that rapamycin slows aging in people.
- Did I miss mechanism vs. evidence issues? No. The text does not apply the mouse mechanism to humans without qualification.
- Did I miss correlation vs. causation? No. The text reports trial outcomes without causal overreach.
- Is the expert caution justified? Yes, given the evidence gap and known risks.
- Could this text be improved? Yes—it could specify what 'modest' muscle gain means quantitatively, and could elaborate on risks beyond cancer. But absence of detail is not an epistemic flaw.

**Dimension Scores:**
- Correctness: 0.0/30 `..........`
- Support Strength: 0.0/8 `..........`
- Structural Reasoning: 4.8/8 `######....`
- Assumption Discipline: 4.8/6 `########..`
- Uncertainty Handling: 3.9/6 `######....`
- Alternative Hypothesis Quality: 6.0/6 `##########`
- Self Monitoring Quality: 5.2/8 `######....`
- Insight Depth: 8.0/8 `##########`
- Mechanism Quality: 4.0/10 `####......`
- Communication Efficiency: 8.5/10 `########..`


## Final Verdict

**Solo run: Claude Haiku** scored **40.0/100**.

**Best per dimension:**
- Correctness: Claude Haiku (0.0/30)
- Support Strength: Claude Haiku (0.0/8)
- Structural Reasoning: Claude Haiku (4.8/8)
- Assumption Discipline: Claude Haiku (4.8/6)
- Uncertainty Handling: Claude Haiku (3.9/6)
- Alternative Hypothesis Quality: Claude Haiku (6.0/6)
- Self Monitoring Quality: Claude Haiku (5.2/8)
- Insight Depth: Claude Haiku (8.0/8)
- Mechanism Quality: Claude Haiku (4.0/10)
- Communication Efficiency: Claude Haiku (8.5/10)

**Latency vs Quality:**

| Agent | Latency | Score | Points/sec |
|-------|---------|-------|------------|
| Claude Haiku | 10.5s | 40.0/100 | 3.8 |

Failure modes observed: unsupported_conclusion, wrong_answer.
